Later developments with immunoliposomes [284,285] or other surface modifications to target markers of vascular damage and platelet activation such as lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), chondroitin sulfate proteoglycans or integrin GPIIb/IIIa, have increased the therapeutic potential of liposomes in cardiovascular diseases [286]. The gene discussed is OLR1; the disease is cardiovascular disorder.